SpringWorks Therapeutics Reported Q4 OGSIVEO Net Product Revenues of $5.4M, EPS Loss of $(1.44) Vs $(1.19) YoY, Cash of $662.6M
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics reported its Q4 earnings, highlighting OGSIVEO net product revenues of $5.4M. The company experienced an EPS loss of $(1.44), compared to $(1.19) year-over-year. Additionally, SpringWorks reported a cash reserve of $662.6M.
February 27, 2024 | 11:39 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
SpringWorks Therapeutics reported a Q4 EPS loss of $(1.44), a decrease from $(1.19) YoY, with OGSIVEO revenues at $5.4M and cash reserves of $662.6M.
The widened EPS loss year-over-year could concern investors, potentially leading to a short-term negative impact on SWTX's stock price. However, the significant cash reserves might mitigate some concerns about the company's financial health.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100